Assessment of the Daily Average Requirement of Iodine in Lactating Women (LISA)

Assessment of the Daily Average Requirement of Iodine in Lactating Women: A Dose-response Metabolic Balance Study

Human milk is the only source of iodine during early infancy and adequate iodine intake during lactation is necessary to assure optimal thyroid function in breastfed infants. However, the physiological requirement of iodine in lactating women is uncertain and recommendations for the daily dietary average requirement are poorly defined. WHO recommends iodine supplementation to lactating women in populations with incomplete coverage of iodized salt and deficient iodine intake, but the scientific evidence is weak and the optimal dose is uncertain.

The primary objective is to assess the daily dietary average requirement for iodine in lactating women.

Secondary objectives are to:

• Estimate the daily average requirement for iodine in exclusively breastfed infants;
• Assess the dose-response of dietary iodine supplements on breast milk iodine concentration in lactating women with adequate and inadequate habitual iodine intakes;
• Estimate the maternal iodine intake required to provide exclusively breastfed infants with an adequate iodine intake via breast milk.

Study Overview

• Status: Recruiting
• Conditions: Healthy; Iodine Deficiency
• Intervention / Treatment: Dietary supplement: Control; Dietary supplement: Iodide (150 μg/day); Dietary supplement: Iodine (300 μg/day)

Detailed Description

This study is a single center, randomized, controlled, dose-response metabolic balance study with cross-over design. The study will be conducted in 24 exclusively breastfeeding women and their infants receding in Zürich, Switzerland. The study involves an initial screening, a 2 weeks run-in period and a balance period over 3 weeks. Participating women will be allocated to two groups based on their consumption of dietary iodine supplements during pregnancy. Women who consumed daily iodine supplements during pregnancy will be assigned to group 1 (n=12) and receive daily supplements containing 150 µg iodine for 2 weeks, whereas women who did not will be enrolled in group 2 and will receive no supplement during the run-in period. Breast milk and spot urine samples (mothers and infants) will be collected daily in all participants during two weeks for the measurement of breast milk and urinary iodine concentrations. During the balance period, all women will receive either no supplement, iodine supplements providing 150 µg/day, or 300 µg/day in random order with cross-over design. Each supplement dose will be assessed in a test period of 7 days, including 2 run-in days, 3 balance days and 2 wash-out days. The supplements will be consumed during the first 5 days in each test-period. During the 3 balance days, the daily iodine intake and excretion will be measured in mothers and infants, and the iodine retention will be calculated for each regimen and study group. The minimum daily average requirement will be determined as the iodine intake where the iodine retention is zero.

• Study Type: Interventional
• Enrollment (Anticipated): 24
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Maria Andersson, Dr. sc.; Phone Number: +41442668462; Email: maria.andersson@kispi.uzh.ch
• Study Contact Backup: Name: Lena Fischer, MSc; Phone Number: +41442668462; Email: lena.fischer@kispi.uzh.ch

Study Locations

• Switzerland
  • Zürich, Switzerland, 8032
    • Recruiting
    • Nutrition Research Unit, University Children's Hospital Zurich
    • Contact: Maria Andersson, Dr. sc.; Phone Number: +41442668462; Email: maria.andersson@kispi.uzh.ch
    • Contact: Lena Fischer, MSc; Phone Number: +41442668462; Email: lena.fischer@kispi.uzh.ch

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 49 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Mother-infant pairs in good health, free of any acute illness or chronic thyroid disease.

Mothers

Inclusion criteria:

1. Consent to enroll herself and her baby;
2. Age 18 to 49 years;
3. Singleton pregnancy;
4. Exclusively breastfeeding;
5. Self-estimated BMI <30 kg/m2 before conception.

Exclusion criteria:

1. TSH >6 mIU/L;
2. Anemia (Hb <11.7 g/L);
3. Pregnancy (self-reported);
4. Acute illness (e.g. gastroenteritis);
5. History of thyroid disease, diabetes, metabolic disease or inflammatory bowel disease (self-reported);
6. Currently smoking (>1 cigarette/day);
7. Drug abuse or extensive alcohol intake;
8. Exposure to iodine-containing X-ray or computed tomography contrast agents during the past 6 months;
9. Adenomatous goiter, dermatitis, anti-C1q-vasculitis.

Infants

Inclusion criteria:

1. Full term (38-42 weeks);
2. Birthweight ≥2.5 kg;
3. Exclusively breastfed;
4. Age 0-10 weeks at recruitment.

Exclusion criteria:

1. Age >6 months;
2. TSH >10 mIU/L at neonatal screening at 2-5 days after birth (i.e. infants not requested to attend recall assessment);
3. Diagnosed or suspected colic.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Basic Science
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Lactating women with assumed adequate habitual iodine intake; Women who consumed iodine-containing dietary supplements during pregnancy (≥150 μg/day). Women in this group will receive a daily oral iodine supplement providing 150 μg iodine as potassium iodide for 14 days before the study start.	Dietary supplement: Control; No iodine; Dietary supplement: Iodide (150 μg/day); A single oral tablet once daily for five days providing 150 μg iodine as potassium iodide; Other Names: Jodetten® 150 Henning, Sanofi-Aventis Germany GmbH, Germany; Dietary supplement: Iodine (300 μg/day); Two oral tablets (150 μg + 150 μg) daily for five days providing 300 μg iodine as potassium iodide; Other Names: Jodetten® 150 Henning, Sanofi-Aventis Germany GmbH, Germany
Experimental: Lactating mothers with assumed inadequate habitual iodine intake; Women who did not consume iodine-containing dietary supplements during pregnancy (≥150 μg/day).	Dietary supplement: Control; No iodine; Dietary supplement: Iodide (150 μg/day); A single oral tablet once daily for five days providing 150 μg iodine as potassium iodide; Other Names: Jodetten® 150 Henning, Sanofi-Aventis Germany GmbH, Germany; Dietary supplement: Iodine (300 μg/day); Two oral tablets (150 μg + 150 μg) daily for five days providing 300 μg iodine as potassium iodide; Other Names: Jodetten® 150 Henning, Sanofi-Aventis Germany GmbH, Germany

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maternal iodine retention (μg/day)	Calculated as iodine intake (µg/day) minus the iodine excretion (µg/day)	24 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maternal iodine excretion in breast milk (μg/day)	Estimated from measured breast milk iodine concentration (μg/L) and breast milk volume (L)	24 hours
Infant iodine retention (μg/day)	Calculated as iodine intake (µg/day) minus the iodine excretion (µg/day)	24 hours

Collaborators and Investigators

• Sponsor: University Children's Hospital, Zurich
• Collaborators: ETH Zurich (Switzerland)
• Investigators: Principal Investigator: Christian Braegger, M.D., University Children's Hospital, Zurich

Publications and helpful links

Helpful Links

• Swiss National Clinical Trials Portal

Study record dates

Study Major Dates

• Study Start (Actual): May 16, 2022
• Primary Completion (Anticipated): November 1, 2023
• Study Completion (Anticipated): July 1, 2024

Study Registration Dates

• First Submitted: May 16, 2022
• First Submitted That Met QC Criteria: May 16, 2022
• First Posted (Actual): May 19, 2022

Study Record Updates

• Last Update Posted (Actual): May 24, 2022
• Last Update Submitted That Met QC Criteria: May 23, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Keywords: Iodine; Infant; Dietary requirement; Lactating women
• Other Study ID Numbers: BASEC2022-00130

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No